South & Central America Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-ba

South & Central America Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)   

The influenza vaccines market in South & Central America is expected to grow from US$ 497.54 million in 2022 to US$ 736.35 million by 2028. It is estimated to grow at a CAGR of 6.8% from 2022 to 2028.

Emerging Economies

Leading players in the influenza vaccines market focus on expanding their customer reach across emerging markets by expanding their distribution networks and augmenting their manufacturing capabilities. In addition, high investments in life science and healthcare research in emerging countries play a crucial role in upgrading the latest technologies in developing countries. In turn, this supports the inclination toward advanced vaccine development. Key producers of influenza vaccines in Brazil is expected to witness lucrative opportunities in the near future due to the large patient pool and high prevalence of influenza, improving healthcare infrastructure, rising disposable income, and the surge of medical tourism in these countries.

Market Overview

South & Central America influenza vaccines market includes Brazil, Argentina, and Rest of South and Central America. The region held smallest portion of the market in the global analysis. The market for influenza vaccines in the region is expected to have growth opportunities during the forecast period. The influenza vaccines market in the South & Central America region is expected to grow owing to factors such as, an increase in cases of influenza in the region, surge in various research activities in the region, increasing awareness, and rising healthcare expenditure by the countries of the region. Brazil has made huge strides in healthcare sector owing to increasing healthcare expenditure. As per the International Trade Administration (ITA), Brazil is the largest healthcare market in Latin America and spends 9.1% of its GDP in healthcare in 2020. The influenza vaccines market in Brazil is expected to flourish owing to factors such as, surge in vaccination programs in the country, and rising healthcare expenditure by the country. In Brazil, influenza epidemics significantly weigh on the Brazilian healthcare system and society, with an estimated number of ILI cases as high as 83 million in a year. Brazil has one of the most extensive immunization programs worldwide. Since 1999, the influenza vaccines has been provided free of charge to older adults (aged 60 years or more) in the whole count. Public health authorities have then progressively expanded the recommendation to the pediatric age groups by first including, in 2011, children aged from 6 months to under 2yo, then under 5yo in 2016, and in 2019 to all children from 6 months to 6 years of age. Vaccination campaigns are nationwide. These campaigns occur every year for two weeks, before the colder season, in all primary healthcare units. The trivalent and inactivated influenza vaccines is produced by a national laboratory (Instituto Butantan) and administered in private health establishments. As per the Journal of Infection and Public Health, Vaccination coverage remained close to the target of 75% proposed by the World Health Organization. The most relevant factors influencing vaccination have been health-related measures; lifestyle and socioeconomic status also played an essential role in predicting vaccines uptake
South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Influenza Vaccines Market Segmentation

The South & Central America Influenza Vaccines Market is segmented into vaccine type, virus type, technology, route of administration, and country.
Based on vaccine type, the South & Central America influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered the larger market share in 2022.
Based on virus type, the South & Central America influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2022.
Based on technology, the South & Central America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger market share in 2022.
Based on route of administration, the South & Central America influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger market share in 2022.
Based on country, the market is segmented into Brazil, Argentina, and the rest of South & Central America. Brazil dominated the market share in 2022.
AstraZeneca; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in South & Central America.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South & Central America Influenza Vaccines Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the Influenza Vaccines Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution